Tandem Diabetes Care is making a major push to expand access to insulin pump therapy. During Canaccord Genuity’s 46th Annual Growth Conference, Tandem outlined plans to make its technology more affordable, expand internationally, and give users more flexibility in how they wear their pumps.

During the presentation, Tandem stated that only about 40% of the roughly 2 million people with type 1 diabetes in the U.S. use insulin pumps, while pump adoption among people with type 2 diabetes is even lower. Earlier this year, Tandem’s pumps received CE Mark approval for use in European countries, which will help the company reach into new markets. This year, Tandem has expanded into the United Kingdom, Switzerland, and Austria with plans to move into France before the end of the year and new European markets already queued up for 2027.

Tandem is shifting more of its U.S. business toward the pharmacy channel. Its pay-as-you-go (PayGo) model allows the pump itself to be provided without the traditional upfront cost, with users paying for supplies through the pharmacy benefits channel. Tandem is converting its current customers by comparing the costs between pharmacy and durable medical equipment (DME), the traditional benefits channel for insulin pumps and supplies. If a user decides to pursue the pharmacy channel, Tandem then has to receive a new prescription from the user’s physician.

Tandem stated that other than affordability, wearability is a major barrier to getting more people started on pump therapy. The tubeless Mobi will give users the option to wear the system with or without tubing. Tandem is also working on extended-wear components that could allow the system to be worn for up to seven days. Users could replace and refill the insulin cartridges in the pump without needing to do a new site change. The tubeless Mobi has been submitted to the FDA, pending regulatory clearance, it is expected to be on the market in 2027.

Mobi will enter an increasingly competitive market, with Insulet’s Omnipod 6, Beta Bionics’s Mint patch pump, and MiniMed Fit all currently in development and offering different approaches to automated insulin delivery. Tandem's strategy is to differentiate not only through the physical design of the pump, but also through its software. The tubeless pump will continue to use the same Control-IQ algorithm but offers a new form factor. The Chief Administrative Officer and Chief Financial Officer stated that the company plans on offering new wearability options first and then strengthening its algorithm, building toward a closed loop system.